RE: Provexis15 Apr 2021 08:29
A reminder from 2017 (click expand to get the full article)
https://translate.google.co.uk/translate?hl=en&sl=zh-CN&u=http://www.sohu.com/a/156312525_648150&prev=search&pto=aue
"Through the above introduction, we can see that the Lerosol" (Fruitflow) "tablets we are going to market this year inhibit the excessive activation of platelets, thereby preventing deep vein thrombosis and pulmonary embolism, reducing the risk of acute myocardial infarction, and preventing sudden exercise death. . At the same time, it can also reduce the release of inflammatory factors, help relieve exercise fatigue, and help shorten the time of exercise recovery. Our recommended taking time is for the general public, especially those over 35 years old. We recommend daily long-term use, and we recommend taking it 1.5-3 hours before strenuous exercise. Regarding Fruitflow® raw materials and products containing the raw materials, we are carrying out human experiments, animal function experiments, and a series of other related functions mechanism research at the same time. In the future, sports cardiovascular protection products will be launched one after another. I hope to have more exchanges with you in the future, thank you."
As we know By-Health were ready to launch there first fruitflow product at the end of 2017. It was then decided that the better route would be to get Blue Cap and a product was only launched to the Chinese national athletes.
2018
"BY-HEALTH has launched a Fruitflow® sports nutrition product in China under its GymMax brand, for the
exclusive use of Chinese national athletes."
https://provexis.org/wp-content/uploads/2018/09/Provexis-plc-annual-report-31-Mar-18-FINAL-TYPESIGNED.pdf
Relevant studies then had to be carried out in China for SAMR submissions.
"The two completed studies (a human study and an animal study) showed excellent results in use for Fruitflow®,
and BY-HEALTH intends to make its first blue cap submission to the SAMR for Fruitflow® in February 2019,
with a further blue cap submission envisaged later in 2019, both to include references to the Company’s
existing European Food Safety Authority (‘EFSA’) health claim for Fruitflow."
https://provexis.org/wp-content/uploads/2018/12/PXS_2018-11_Provexis_plc_30-Sep-18_interims_31-Dec-18.pdf
Once the submissions are made to SAMR there is very little By-Health can do but wait and we know SAMR is not a quick process, although it is getting quicker, and we don't know how many Blue Cap submissions have been made so far for Fruitflow but I am sure it will be worth the wait. :)
"cardiovascular protection products will be launched one after another"
Sign In
Follow the stocks
